CYP 2D6 polymorphism and antipsychotic therapy.
One of the most challenging problems in clinical psychiatry are inter-individual differences in clinical response to antipsychotic treatment. Several studies were investigating the impact of the polymorphic cytochrome P450 2D6 gene (CYP 2D6) on the psychopathological and extrapyramidal symptoms, but the results were conflicting. There is a lack of clinical studies of the impact of CYP2D6 polymorphism on therapeutic efficacy, especially in the long-term treatment of schizophrenia. The aim of the presentation was to evaluate the impact of CYP2D6 genotype on psychopathological and extrapyramidal symptoms in a group of Slovenian outpatients with schizophrenia or schizoaffective disorder in stable remission, who were receiving long-term maintenance therapy.
Plesnicar
Blanka Kores
BK
University Clinical Centre Maribor, Department of Psychiatry, and Medical faculty Maribor, Slovenia. blanka.kores@ukc-mb.si
Dolzan
Vita
V
Zalar
Bojan
B
D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control; D015984:Causality; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008134:Long-Term Care; D008137:Longitudinal Studies; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control; D017524:Slovenia; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D019389:Cytochrome P-450 CYP2D6